Forest Credits Lexapro Growth To Less Detailing By Competitors
This article was originally published in The Pink Sheet Daily
Executive Summary
The antidepressant market has “normalized” following suicidality concerns, COO Goodman says.
You may also be interested in...
Forest Labs Expects “Modest” Lexapro Gain From Generic Zoloft Launch
Company expects Lexapro to continue to gain ground in SSRI market although promotional spend will not increase significantly.
Forest Labs Expects “Modest” Lexapro Gain From Generic Zoloft Launch
Company expects Lexapro to continue to gain ground in SSRI market although promotional spend will not increase significantly.
Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.